Pharmaceutical Technology on MSN16d
Sanofi’s Sarclisa combo approved in Japan for newly diagnosed MM
Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction with bortezomib, lenalidomide and dexamethasone (VRd) to treat adults with ...
WebMD3y
Multiple Myeloma Resource Center
Your risk for multiple myeloma (MM) increases as you age. The average age for this type of blood cancer is 70. Multiple myeloma is a rare type of blood cancer. The chances of getting it are 1 in 132.